ТАНКВИСТ Браян Дж. (US),ВОКЕР Дункан Х. (US),ВОСНЕР Ричард Дональд (US)
申请号：
RU2011119427/15
公开号：
RU2011119427A
申请日:
2009.10.16
申请国别(地区):
RU
年份:
2012
代理人:
摘要：
1. The compound (S) -2- (3-aminopropyl) -5- (2,5-difluorophenyl) -N-methoxy-N-methyl-2-phenyl-1,3,4-thiadiazole-3 (2H) - carboxamide for administration to a patient having pathogenic cells in a state of delay in mitosis induced by this compound in order to intensify the apoptosis process of the cells, which is administered at the maximum tolerated dose. 2. The administration compound according to claim 1, wherein the pathogenic cells are cancer cells. The administration compound according to claim 1, wherein the pathogenic cells are tumor blood cells. The administration compound according to claim 1, wherein the pathogenic cells are selected from lymphoma, leukemia and multiple myeloma cells. The administration compound according to claim 1, wherein the pathogenic cells are solid tumor cells. The administration compound according to claim 1, wherein the pathogenic cells are selected from tumor cells of the skin, breast, brain, cervical carcinoma, and testicular carcinoma cells. The administration compound according to claim 1, wherein the pathogenic cells are selected from breast cancer cells, colorectal cancer, non-small cell lung cancer, pancreatic cancer, bladder cancer, salivary gland cancer (adenoid cystic), esophageal cancer, malignant mesothelioma and mixed small cell cancer lung / non-small cell lung cancer. 8. A compound for administration according to any one of claims 1 to 7, wherein administration is on the 11-17th day of the cycle. The administration compound of claim 8, wherein the first dose of the compound provides cells in a state of delay in mitosis induced by this compound, is administered on the first day, and the second dose, causing an intensification of the apoptotic process of cells, is administered on the second day. Connection for the introduction of p.1. Соединение (S)-2-(3-аминопропил)-5-(2,5-дифторфенил)-N-метокси-N-метил-2-фенил-1,3,4-тиадиазол-3(2Н)-карбоксамид для введения пациенту, имеющему патогенные клетки в состоянии задержки в ми
